Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Croci
Alberto Croci, Muenchen DE
| Patent application number | Description | Published |
|---|---|---|
| 20080242504 | Shifting Point Display in a Motor Vehicle Having a Manual Transmission - A shifting point display for indicating shift advice is provided in a motor vehicle having a manual transmission and a control unit for the continuous determination of a current operating point of the motor vehicle. At least one characteristic upshift indication curve or a characteristic downshift indication curve is stored in an electronic memory. An upshift indication or a downshift indication is displayed when the characteristic upshift indication curve or the characteristic downshift indication curve is reached by the current operating point and a currently differently engaged gear. The upshift indication or the downshift indication is indicated until the driver has carried out a corresponding upshift operation or downshift operation or until the current operating point has reached and/or fallen below a characteristic upshift indication hysteresis curve that is smaller than the characteristic upshift indication curve, or has reached and/or exceeded a characteristic downshift indication hysteresis curve that is greater than the characteristic downshift indication curve. | 10-02-2008 |
Alessandro Luciano Croci, Nerviano (mi) IT
| Patent application number | Description | Published |
|---|---|---|
| 20120114641 | THERAPEUTIC COMBINATION COMPRISING A PLK1 INHIBITOR AND AN ANTINEOPLASTIC AGENT - The present invention provides a combination comprising (a) a compound of formula (I) and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, analkylating or alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome inhibitor and an antibody inhibiting a growth factor or its receptor, wherein active ingredients of the combination are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate or solvate thereof, useful in the treatment of tumors. | 05-10-2012 |
Marco Croci, Carate Brianza (mi) IT
| Patent application number | Description | Published |
|---|---|---|
| 20100239259 | OFDM Transponder Interface With Variable Bit Transfer Rate in Optical Communications Systems - OFDM (Orthogonal Frequency Division Multiplexing) has been proposed for processing signals over WDM channels in an optical network. The number of OFDM sub-carrier channels utilized in transmitting optical signals from a transmitting node to a remote is adapted to the quality of transmission in a WDM channel. Responsive to control signals from the remote node, the number of used sub-carrier channels is set to optimize optical performance of the WDM channel. | 09-23-2010 |
Tiziano Croci, Milan IT
| Patent application number | Description | Published |
|---|---|---|
| 20090124643 | Use of a Cannabinoid CB1 Receptor Antagonist for Preparation of Drugs Useful for the Prevention and Treatment of Benign Prostatic Hypertrophy - The present invention relates to the use of cannabinoid CB1 receptor antagonist for the preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy. | 05-14-2009 |
| 20100075986 | Oxophenyl-Cyclohexyl-Propanolamine Derivatives, Production And Use Thereof In Therapeutics - The invention relates to the compounds of general formula (I) | 03-25-2010 |
Tiziano Croci, Milano IT
| Patent application number | Description | Published |
|---|---|---|
| 20080261949 | CYCLOHEXYL(ALKYL)PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME - The present invention relates to the compounds of formula (I): | 10-23-2008 |
Valter Domenico Croci, Nerviano (mi) IT
| Patent application number | Description | Published |
|---|---|---|
| 20110312909 | THERAPEUTIC COMBINATION COMPRISING A CDKS INHIBITOR AND AN ANTINEOPLASTIC AGENT - The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of alkylating or alkylating-like agents, antimetabolite agents and topoisomerase I inhibitors, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof. | 12-22-2011 |
| 20120114641 | THERAPEUTIC COMBINATION COMPRISING A PLK1 INHIBITOR AND AN ANTINEOPLASTIC AGENT - The present invention provides a combination comprising (a) a compound of formula (I) and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, analkylating or alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome inhibitor and an antibody inhibiting a growth factor or its receptor, wherein active ingredients of the combination are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate or solvate thereof, useful in the treatment of tumors. | 05-10-2012 |